Facebook
X
LinkedIn
Forward
KASTRO/KOSRO Joint Activity: Radiation Therapy for Nonmalignant Disease: Transcontinental Perspectives on Newer Indications from Korea and the United States
While best known for its use in cancer, radiotherapy (RT) can be used as a successful treatment for several nonmalignant diseases. Nonetheless, the use of non-oncological RT is uncommon, and its utilization varies from country to country. Even though the use of RT for nonmalignant disease has been investigated since the discovery of X-ray, new indications are being explored, especially with the development of new technologies. Jointly sponsored by the Korean American Society for Therapeutic Radiation Oncology (KASTRO) and the Korean Society for Radiation Oncology (KOSRO), this activity aims to share transcontinental perspectives from Korea and the United States on emerging areas of RT use for nonmalignant disease, including refractory osteoarthritis, Alzheimer’s disease, and refractory ventricular tachycardia. This activity is particularly timely given the aging population of patients suffering from these conditions, with Korean researchers leading efforts to develop new whole-brain RT delivery technology for Alzheimer’s disease. In addition to a discussion of current evidence and future research opportunities, practical considerations for equitable patient selection, optimal treatment planning/delivery, and program development in diverse academic and community settings in two different countries are explored.
Topics:
- Low-dose Irradiation for Neurodegenerative Disease
Weon Kuu Chung, MD, PhD - Radiation Therapy for the Treatment of Osteoarthritis
James B. Yu, MD, FASTRO, MHS - Cardiac Radioablation for Ventricular Tachycardia
Ji Hyun Chang, MD, PhD - Q and A
Stella K. Yoo, MD - Moderator
Full Panel
This activity is available from July 28, 2026, through 11:59 p.m. Eastern time on July 27, 2028.
The content was originally presented and recorded at the 2025 ASTRO Annual Meeting.
Target Audience
The activity is designed to meet the interests of medical oncologists, radiation oncologists, surgeons, physicists, radiation therapists, radiation dosimetrists and residents.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Identify the benefits and limitations of low-dose irradiation for osteoarthritis and receive a refresher on practice guidelines.
- Identify the benefits and limitations of low-dose irradiation for neurodegenerative disease and explore its technological development and clinical use.
- Identify the challenges and potential benefits of radioablation for refractory arrhythmia and discuss technological advancement leading to the expansion of non-oncologic RT indications.
Moderator:
- Stella K. Yoo, MD, is employed by Los Angeles General Medical Center. Dr. Yoo has no relevant financial relationship with ineligible companies to disclose.
Speakers:
- Weon Kuu Chung, MD, PhD, is employed by Kyunghee University Hospital at Gangdong. Dr. Chung has no relevant financial relationship with ineligible companies to disclose.
- James B. Yu, MD, FASTRO, MHS, is employed by Dartmouth Cancer Center. Dr. Yu receives honoraria from Boston Scientific and Pfizer/Myovant. Dr. Yu receives grant/research funding from Pfizer/Myovant. Dr. Yu owns stock in Modifi Bio.
- Ji Hyun Chang, MD, PhD, is employed by Seoul National University College of Medicine. Dr. Chang has no relevant financial relationship with ineligible companies to disclose.
Planners:
- Malcolm Mattes, MD, is employed at Rutgers Cancer Institute. Dr. Mattes received research/grant funding from Gilead Sciences (relationship ended 8/30/2025). Dr. Mattes has no relevant financial relationship with ineligible companies.
- Parul Barry, MD, is employed by the University of Pittsburgh Medical Center. Dr. Barry has no relevant financial relationship with ineligible companies.
- Michael Haddock, MD, is employed by Mayo Clinic and has no relevant financial relationship with ineligible companies to disclose.
- Manisha Palta, MD, is employed by Duke Cancer Center and Duke University Hospital. Dr. Palta receives grant/research funding from Merck and Varian Medical Systems.
- Salma Jabbour, MD, is employed by Rutgers Cancer Institute. Dr. Jabbour receives grant/research funding from Merck & Co., Inc. and Beigene. Dr. Jabbour receives compensation/payment as a consultant with Radialogica and IMX Medical.
All relevant financial relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Available Credit
- 1.00 AMA PRA Category 1 Credit™
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.00 Certificate of AttendanceThis activity was designated for 1.00 AMA PRA Category 1 Credit™.
Price
Course Fees:
ASTRO members must log in to the ASTRO website to view and receive the member rate.
- Nonmember: $149
- Member: $99
- Member-in-Training: $49
- Student/Graduate Student/PGY-1 Member: $49
- Postdoctoral Fellow Member: $49
If you are an ASTRO member from a low or lower-middle income country, as identified by the World Bank, you can receive a 50% discount off your corresponding registration for this activity. Please email [email protected] to inquire about the discount.
Policies:
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the activity by the expiration date.
Participants using ASTRO Academy activities to satisfy the requirement of a Continuing Certification (MOC) program should verify the credit number and type and availability dates of any activity before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased activities that do not align with their MOC requirement.
The activity and its materials will only be available on the ASTRO website until July 27, 2028, regardless of purchase date. At the expiration of the activity, participants will no longer have access to the activity or its materials. ASTRO reserves the right to remove an activity before its expiration date.
Required Hardware/software
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.